Ajanta Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Ajanta Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 2609.7, up 0.12% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.09% on the day, quoting at 26009.55. The Sensex is at 85089.75, down 0.02%. Ajanta Pharma Ltd has risen around 1.59% in last one month.

Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has risen around 2.76% in last one month and is currently quoting at 22907.85, down 0.19% on the day. The volume in the stock stood at 19677 shares today, compared to the daily average of 72529 shares in last one month.

The PE of the stock is 34.25 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Ajanta Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2596, up 1.3% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.48% on the day, quoting at 26049.4. The Sensex is at 85227.88, down 0.48%. Ajanta Pharma Ltd has gained around 2.23% in last one month.

Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has gained around 1.98% in last one month and is currently quoting at 22887.75, down 0.01% on the day. The volume in the stock stood at 61812 shares today, compared to the daily average of 89941 shares in last one month.

The PE of the stock is 33.66 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Ajanta Pharma has fixed 10 November 2025 as record date for payment of first interim dividend.

Powered by Capital Market - Live News

Revenue from operations rose 14.08% YoY to Rs 1,353.73 crore for the quarter ended 30 September 2025.

Profit before tax (PBT) stood at Rs 340.81 crore in Q2 FY26, up 17.42% from Rs 290.24 crore reported in the same quarter last year.

EBITDA stood at Rs 328 crore in Q2 FY26, up 5.46% as against 311 crore posted in same quarter last year. EBITDA margin was at 24% in Q2 FY26 as against 26% in Q2 FY25.

During the quarter, the company?s revenue from India stood at Rs 432 crore (up 12% YoY), revenue from Asia was at Rs 310 crore (up 5% YoY), revenue from Africa stood at Rs 221 crore (up 4% YoY) revenue from Africa institution was at Rs 32 crore (down 25% YoY) while revenue from US Generic was at Rs 344 crore (up 48% YoY).

As per IQVIA MAT September 2025, Ajanta Pharma?s India branded generic performance exceeded IPM growth by 32%. The higher growth came from Volumes increase, which exceeded IPM by 115% & new launches, which exceeded IPM by 39%.

On a half-year basis, the company?s consolidated net profit rose 11.52% to Rs 515.53 crore on a 13.93% increase in revenue to Rs 2,656.38 crore in H1 FY26 compared with H1 FY25.

Meanwhile, the company?s board of directors declared a first interim dividend of Rs 28 per share for FY26. The record date for the dividend is 10 November 2025 and the dividend will be paid on or after 20 November 2025.

Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified branded generics business spread across India, the Rest of Asia, and Africa. The company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments.

Powered by Capital Market - Live News